NEI Podcast

E160 - (CME) Novel Agents for Treating Major Depressive Disorder (MDD)

Sep 26, 2022
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
The Monoma Mean Hypothesis
02:29 • 2min
3
The Role of Serotonin in Theology of MDD
04:04 • 3min
4
The Relationship Between Symptoms and MDD
06:42 • 2min
5
The Clinical Relevance of Antidepressants
08:41 • 4min
6
The Importance of Cognitive Scars
12:17 • 2min
7
The Role of Neurons in Major Depressive Disorder
14:18 • 2min
8
GABA and Glutamic Signaling in Depression
16:48 • 2min
9
The Role of GABA in Depression
19:12 • 3min
10
The Negative Cognitive Bias of Repeated Episodes
22:05 • 2min
11
The Effects of Psychedelics on Depression
24:03 • 2min
12
The Effects of Kappa Opioids on Depression
25:58 • 2min
13
The Effects of Zeranolone on GABAA Receptors
27:42 • 3min
14
The New Paradigm of Intermittent Treatment
30:54 • 2min
15
The Effects of Multimodal Agents on NMDA Receptors
32:57 • 2min
16
Dextromathorfen: A Novel Antidepressant
34:37 • 2min
17
The Effects of Texturmethorphin on Neurotransmitter Synthesis
36:34 • 2min
18
The Role of Neurosteroids in Cognition Learning Memory
38:53 • 3min
19
Ketamine and Eschitamine: A Comparison
41:32 • 4min
20
The Benefits of Racemic Ketamine
45:06 • 2min
21
The Role of Ketamine in the Treatment of Depression
47:01 • 3min
22
Psychedelics: What We Know So Far
49:52 • 2min
23
The Role of Psychedelics in Brain Network Strength
52:21 • 2min
24
The Paradigm Shift in Psychopharmacology
54:10 • 3min
25
The Role of Physical Activity in Depression
57:37 • 2min
26
The Importance of Epigenetic Testing in Antidepressants
59:12 • 3min
27
The Role of Genes in Antidepressants
01:01:59 • 2min
28
The Importance of Knowledge Transfer
01:04:07 • 2min